The German Society for Rheumatology (DGRh) is recommending that people with inflammatory rheumatic diseases undergo early medical assessment of their cardiovascular risk, in line with the S3 guideline. The advice comes ahead of World Arthritis Day on 12 October, according to ad-hoc-news.de.
Roughly 1.8 million adults in Germany are estimated to live with an inflammatory rheumatic condition, the outlet reports. Rheumatoid arthritis and spondyloarthritis each account for about 700,000 of those cases.
Why it matters
Persistent inflammation does not stay confined to the joints. According to the specialist society, the chronic inflammatory processes associated with these conditions place added strain on the vascular system.
Ad-hoc-news.de reports that the risk of heart attack is around 40 percent higher in people with rheumatoid arthritis. For spondyloarthritis, the elevated risk ranges between 21 percent and 51 percent depending on the analysis, alongside a moderately increased risk of stroke.
The DGRh's guidance is that this risk should be evaluated by a physician early rather than left to surface as a cardiac event.
What CRP reveals about disease activity
The recommendation sits alongside broader clinical interest in inflammatory markers, particularly C-reactive protein, whose relevance for early detection in rheumatology and neurology has been the subject of specialist commentary.
CRP is an acute-phase protein produced in the liver. Following a triggering event such as tissue damage or infection, its concentration in the blood becomes measurable within four to six hours. The physiological reference range is 0 to 5 mg/L, and values above 10 mg/L are considered pathological in clinical assessment.
In routine practice, a pronounced rise above 100 mg/L signals the need for further diagnostic work. Values at that level are most often caused by bacterial infections such as pneumonia, pyelonephritis or appendicitis. By contrast, readings around 50 mg/L can also be consistent with viral infections.
Standard CRP tests capture systemic inflammation from 10 mg/L upward, while high-sensitivity tests (hs-CRP) are used chiefly to assess overall cardiovascular risk.
The marker also has a role in monitoring recovery. After surgery with an uncomplicated course, values fall again; persistently elevated readings point to secondary bacterial complications. CRP does not deliver a diagnosis on its own, which is why treatment targets the underlying cause.
In autoimmune conditions including rheumatoid arthritis, systemic lupus erythematosus (SLE) and ankylosing spondylitis, the CRP level reflects disease activity — the context in which the DGRh's cardiovascular advice is framed.
Markers in neurological injury
Beyond rheumatology, marker profiles are gaining ground in the assessment of neurological damage, according to the same reporting.
In acute events such as brain injury, CRP typically peaks 24 to 48 hours after the primary incident. Cell-specific proteins are used alongside it to map neurological trajectories early.
One of these is the protein S100B, which has a half-life of roughly 30 to 120 minutes and whose values correlate negatively with the Glasgow Coma Scale (GCS).
For neuron-specific enolase (NSE), which has a plasma half-life of about 24 hours, ERC and ESICM guidelines define threshold values for prognosis. A peak above 33 µg/L between 48 and 72 hours after successful resuscitation (ROSC) indicates an unfavourable neurological outcome with a specificity close to 100 percent. Reliable measurement requires avoiding haemolysis in samples and separating serum or plasma within 30 minutes.
What to watch
World Arthritis Day on 12 October puts the DGRh's screening advice in front of patients and clinicians. The practical question is whether cardiovascular assessment becomes a routine part of rheumatology follow-up for the roughly 1.8 million adults in Germany living with these conditions.
